The company's device has a proprietary added functionality that reduces bacterial growth, potentially reducing catheter-associated urinary tract infections. Additionally, it can be used for targeted therapeutic delivery to the urinary tract, providing physicians with a new treatment modality to improve patient outcomes. Portela Soni Medical is focused on reducing infections and improving outcomes for patients, with their urinary catheter currently in R&D and set to file for FDA 510(k) in 2018. For more information or to offer support, follow them on Twitter or send them a note.